Deutsche Bank AG Has $1.67 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Deutsche Bank AG raised its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 51.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 70,961 shares of the company’s stock after buying an additional 24,104 shares during the quarter. Deutsche Bank AG owned about 0.07% of Dyne Therapeutics worth $1,672,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. abrdn plc acquired a new stake in Dyne Therapeutics during the fourth quarter worth about $608,000. Raymond James Financial Inc. bought a new stake in shares of Dyne Therapeutics during the fourth quarter valued at approximately $2,340,000. Barclays PLC increased its position in shares of Dyne Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 207,309 shares of the company’s stock valued at $7,446,000 after purchasing an additional 128,246 shares during the period. Schroder Investment Management Group raised its stake in shares of Dyne Therapeutics by 63.3% in the fourth quarter. Schroder Investment Management Group now owns 147,002 shares of the company’s stock valued at $3,477,000 after purchasing an additional 56,961 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in Dyne Therapeutics by 54.5% in the fourth quarter. Wells Fargo & Company MN now owns 38,754 shares of the company’s stock worth $913,000 after purchasing an additional 13,677 shares during the period. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Trading Down 1.8%

Shares of NASDAQ DYN opened at $11.69 on Friday. The company has a fifty day moving average price of $10.32 and a 200 day moving average price of $16.92. The firm has a market cap of $1.33 billion, a PE ratio of -3.28 and a beta of 1.19. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). Equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on DYN shares. Scotiabank began coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price target on the stock. Chardan Capital reiterated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Friday, May 9th. JPMorgan Chase & Co. dropped their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. Piper Sandler cut their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Finally, BMO Capital Markets began coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $47.25.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.